Affiliation
Date
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patients with acute ischaemic stroke who meet strictly defined criteria. IST-3 sought to improve the external validity and precision of the estimates of the overall treatment effects (efficacy and safety) of rtPA in acute ischaemic stroke, and...
Description
Keywords
Medicine (General) , Neurologi , Acute Disease; Brain Ischemia drug therapy; Double-Blind Method, Fibrinolytic Agents; Humans; Prospective Studies; Sample Size; Stroke drug therapy; Thrombolytic Therapy; Tissue Plasminogen Activator , 610 , Medicine (miscellaneous) , R Medicine , Research & Experimental Medicine , Update , Brain Ischemia , R5-920 , ALTEPLASE , Double-Blind Method , Fibrinolytic Agents , IST-3 collaborative group , General & Internal Medicine , double-blind method , Humans , Pharmacology (medical) , Thrombolytic Therapy , Prospective Studies , humans , 1102 Cardiorespiratory Medicine and Haematology , acute disease , thrombolytic therapy , tissue plasminogen activator , Science & Technology , Research & Experimental , R , 1103 Clinical Sciences , stroke , brain ischemia , prospective studies , sample size , Stroke , Neurology , Medicine, Research & Experimental , Cardiovascular System & Hematology , fibrinolytic agents , Sample Size , Tissue Plasminogen Activator , Acute Disease , Medicine , Life Sciences & Biomedicine